Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06362265 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
A Phase 1 study of Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 10
- Study locations
NCT06362265 is a Phase 1 study of Type 2 Diabetes Mellitus that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 22 participants, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT06362265, a Phase 1 study of Type 2 Diabetes Mellitus, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 10
- Study locations
Study Summary
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Conditions Studied
Interventions
- DRUG LY3209590
Study Locations (10)
Georgia
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics - Atlanta
- Centricity Research Columbus Endocrinology - Columbus
New York
- UBMD Pediatrics - Buffalo
- NYU Langone - New York
California
- Children's Hospital Los Angeles - Los Angeles
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Joslin Diabetes Center - Boston
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Lifedoc Research - Lenox Park Drive - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06362265
The ClinicalTrials.gov registry entry for NCT06362265 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,748-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which LY3209590 is the first listed.
NCT06362265 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Georgia, New York, California.
Frequently Asked Questions
What is clinical trial NCT06362265 about?
NCT06362265 is a clinical study titled "A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus". The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
What is the current status of trial NCT06362265?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2024-10-10. Estimated completion is 2026-11.
What conditions does trial NCT06362265 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT06362265?
The interventions under investigation include: LY3209590 (DRUG).
Who is sponsoring clinical trial NCT06362265?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06362265 being conducted?
This trial has 10 study locations across California, Georgia, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
COMPLETED · Phase 1
-
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
COMPLETED · Phase 1
-
A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol
COMPLETED · Phase 1
-
Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 1
-
Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.